	Control group	Gastric dysplasia	GC, total	Non-advanced intestinal	Non-advanced diffuse	Advanced intestinal	Advanced diffuse
Gastric patients							
N of patients	10	10	68	17	17	17	17
Age	56.4±16.3	59.3±12.5	61.9±11.4	66.4±14.1	62.1±10.4	66.2±15.3	60.12±14.36
Male/Female	5/5	6/4	32/35	9/8	3/11	11/6	9/8
Colon patients			1 1				
	Control group	Hyperplastic polyps	Sessile serrated polyp	Tubular/villous adenoma	CRC total	Non-advanced	Advanced
N of patients	10	10	10	10	40	20	20
Age	52.4±18.1	58.3±14.7	52.2±18.2	61.3±14.5	64.3±9.6	68.23±12.5	64.2±12.1
Male/Female	5/5	5/5	4/6	5/5	21/19	12/8	11/9

Table S1 Patients characteristics

GC, gastric cancer; CRC, colorectal cancer.




Figure S1 Statistical analysis of IHC scores. TM9SF4 (A), CEA (B), and CA19-9 score values in gastric (left column), and colon (right column). Dots represent mean scores pf each IHC sample. Symbols represent each individual score. Statistically significant differences from the control sample were determined by ordinary one-way ANOVA with Dunnett's post hoc test; significance level alpha was set to 0.05. Errors-bars are SDs. Exact P values for each sample set are shown on the graphs. CEA, carcinoembryonic antigen; GC gastric cancer; CRC, colorectal cancer.